Monoclonal antibody LYM-1-I-131
Alternative Names: LYM-1-I-131; OncolymLatest Information Update: 11 Jan 2018
At a glance
- Originator Northwestern University
- Developer Peregrine Pharmaceuticals
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; B cell inhibitors; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma
Most Recent Events
- 05 Jan 2018 Peregrine Pharmaceuticals is now called Avid Bioservices
- 18 Aug 2003 LYM-1-I-131 is available for licensing
- 19 Jun 2001 Peregrine reacquires the worldwide commercialisation rights to LYM-1-I-131 from Schering AG